Tiziana Life Sciences PLC's (LON:TILS) (NASDAQ:TLSA) Dr Howard Weiner speaks to Proactive's Polly Middlehurst following the news it's submitted a patent application covering the potential use of nasally-administered and orally taken Foralumab for the treatment of COVID-19. Dr Weiner is chairman of Tiziana’s scientific advisory board. The methods of delivering the fully human anti-CD3 monoclonal antibody (mAb) could potentially modulate or stimulate the immune system to suppress cytokine storms and therefore reduce respiratory failure in coronavirus patients.
Tiziana Life Sciences 'very excited' about potential for nasal delivery of Foralumab for coronavirus
Quick facts: Tiziana Life Sciences PLC
Price: 175 GBX
Market Cap: £333.48 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE